Clopidogrel Tablet, Film Coated
Product Images NDC 71205-073

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 71205-073). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Clopidogrel Fig1)

A horizontal bar chart illustrating the effect of co-administered proton pump inhibitors (PPIs) Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg on the active metabolite area under the curve (AUC) of Clopidogrel Bisulfate 75 mg. The x-axis shows change relative to clopidogrel administered alone, with confidence intervals for each PPI's effect.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

A line graph showing cumulative event rates (%) over 12 months of follow-up for cardiovascular death, myocardial infarction, and stroke. Two groups are compared: one receiving placebo plus aspirin, showing higher cumulative events, and another receiving clopidogrel bisulfate plus aspirin, with lower cumulative events. The graph includes a p-value indicating statistical significance and notes additional standard therapies may have been used.*

FDA Label Image

Figure-3 (Clopidogrel Fig3)

A forest plot chart depicting hazard ratios with 95% confidence intervals for Clopidogrel Bisulfate versus placebo across various subgroups, including age, gender, race, enzyme elevation, diabetes status, previous myocardial infarction, previous stroke, anticoagulant use, aspirin dosage, and other medications. The chart compares the number and percentage of events in each subgroup and visually represents whether Clopidogrel Bisulfate or placebo is favored.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

A line graph depicting the percentage of deaths before first discharge over time since randomization, up to 28 days. Two curves compare outcomes for placebo and clopidogrel groups, with the placebo group showing a higher percentage of deaths (8.1%) versus clopidogrel (7.5%). The graph notes a 7% proportional risk reduction for clopidogrel with a statistical significance (p = 0.03).*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

A Kaplan-Meier curve comparing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days, between placebo and Clopidogrel groups. The graph shows a lower event rate with Clopidogrel versus placebo, indicating a 9% proportional risk reduction (p = 0.002).*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

A forest plot displaying odds ratios with 99% confidence intervals for Clopidogrel Bisulfate versus placebo. The plot compares subgroups based on gender, age at entry, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use, showing the relative odds favoring either Clopidogrel Bisulfate or placebo for each subgroup and overall.*

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

A line graph titled 'Fatal or Non-Fatal Vascular Events' comparing cumulative event rates (%) over 36 months of follow-up for Aspirin and Clopidogrel Bisulfate. The graph shows two upward trending lines indicating event rates for each treatment, with a p-value of 0.045 noted on the chart.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

A hazard ratio forest plot comparing Clopidogrel Bisulfate versus Aspirin across qualifying conditions including Stroke, MI, PAD, and Overall. The horizontal axis shows hazard ratios with 95% confidence intervals, indicating preference for Clopidogrel or Aspirin per condition. Data includes sample sizes and event percentages for each group.*

FDA Label Image

71205-073-90 (Clopidogrel Fig9)

Label for Clopidogrel 75 mg film-coated tablets by Proficient Rx LP. The label indicates a quantity of 30 tablets and specifies that each tablet contains 97.875 mg clopidogrel bisulfate USP equivalent to 75 mg clopidogrel base. The product is manufactured by Aurobindo Pharma Limited, Hyderabad, India. Storage instructions are to keep at 20°-25°C (68°-77°F) and out of reach of children. The label includes a barcode, QR code, and various lot and expiration placeholders.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

Chemical structure of clopidogrel bisulfate, showing its molecular arrangement including rings, chlorine atom, and sulfate group indicated as H2SO4.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.